From early-stage funding to growth capital, we guide scientific breakthroughs from proof-of-concept to commercial success. Our hands-on approach to support Australian research is a first-in-country model.
Endo Axiom (Endo) is a cutting-edge platform technology harnessing liver-specific nanoparticles, set to revolutionise diabetes treatment.
Established by esteemed academics from the University of Sydney and Sydney Local Health District, Endo Axiom secured a $2.2 million investment from Proto Axiom. As a proud member of the Proto Axiom family, Endo benefits from comprehensive commercial, technical, and financial support from Proto.
Dr. Nicholas Hunt, CEO of Endo, holds a Senior Lecturer position at Concord Clinical School and is a recipient of the MRFF Targeted Translation Research Accelerator (TTRA) and Sydney Research Accelerator (SOAR) awards. Joining him in this venture are co-founders Prof. David Le Couteur AO and Prof. Victoria Cogger, with Lawrence Gozlan presiding as Chairman.
A spin-out from the University of New South Wales, Swan Genomics was founded in 2023 by academic founders Dr. Lawrence Lee and Min Huang, together with highly regarded US-based industry experts, Dr. Brock Siegel and Dr. Bill Hyun. Swan Genomics has secured $2m in funding from Proto Axiom, and benefits from the full suite of Proto Axiom’s incubation services.
Lawrence Lee is a Chief Investigator at the ARC Centre of Excellence in Synthetic Biology and Associate Professor at the Department of Molecular Medicine, at the University of New South Wales. He was awarded his PhD from the University of Sydney before undertaking a postdoctoral position at the Victor Chang Cardiac Research Institute and an European Molecular Biology Organisation Fellowship at the University of Oxford. He has been recognised numerous awards and honours including an ARC Discovery Early Career Research Award, the National Association of Research Fellows Young Investigator of the Year and a NSW Tall Poppy Award.
